AnGes, Inc.
Stock Price Chart
2026/09/21 UpdatedPrice Trend
2026/09/21 UpdatedPrice & Trading Details
2026/09/21 UpdatedPRICE
TRADING
Earnings Calendar
Updated 2026/09/01Shareholder Composition
Updated 2026/09/01Major Holders
Updated 2026/09/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
SPDR INDEX SHARES Fd.S-State Street SPDR S&P Intl Small Cap ETF
|
85.6K | +1.42% |
Financial Performance
2026/09/20 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥67M | ¥153M | ¥644M | ¥874M |
| Gross Profit | -¥27M | ¥19M | ¥248M | ¥320M |
| Operating Income | -¥16,317M | -¥11,968M | -¥9,109M | -¥5,145M |
| Pretax Income | -¥16,317M | -¥11,968M | -¥9,109M | -¥5,145M |
| Net Income | -¥14,715M | -¥7,438M | -¥28,129M | -¥5,123M |
| EPS | -¥94.29 | -¥39.29 | -¥119.53 | -¥14.44 |
| Operating Margin | -24,331.65% | -7,822.66% | -1,415.31% | -588.64% |
| Balance Sheet | ||||
| Total Assets | ¥38,821M | ¥28,893M | ¥4,669M | ¥5,406M |
| Total Equity | ¥30,425M | ¥26,103M | ¥2,157M | ¥3,076M |
| Total Liabilities | ¥8,395M | ¥2,789M | ¥2,512M | ¥2,330M |
| Cash | ¥11,035M | ¥4,160M | ¥1,708M | ¥1,882M |
| Interest-bearing Debt | ¥1,156M | ¥363M | ¥272M | ¥54M |
| Equity Ratio | 78.37% | 90.35% | 46.19% | 56.90% |
| D/E Ratio | 0.04 | 0.01 | 0.13 | 0.02 |
| Cash Flow | ||||
| Operating CF | -¥11,214M | -¥8,746M | -¥6,613M | -¥5,750M |
| Investing CF | -¥97M | -¥357M | -¥131M | ¥19M |
| Financing CF | ¥3,573M | ¥2,036M | ¥4,202M | ¥5,902M |
| Free CF | -¥11,234M | -¥8,835M | -¥6,690M | -¥5,765M |
| Efficiency | ||||
| ROE | -48.36% | -28.49% | -1,304.33% | -166.55% |
| ROA | -37.90% | -25.74% | -602.51% | -94.77% |
Latest IR Information
-
Announcement on Completion of Acquisition and Cancellation of the 46th Stock Acquisition Rights (with Exercise Price Adjustment Clause)
Acquired and cancelled 837,171 units of the 46th stock acquisition rights. Total acquisition price: 27,626,643 yen. Remaining rights after cancellation: 0. Expected minimal impact on consolidated results for the fiscal year ending December 2026.
Read more -
Notice of Completion of Redemption of the 2nd Unsecured Bond (Private Placement)
Announced the complete redemption of the outstanding 2nd unsecured bond as of August 14, 2026. Redemption amount is total face value of 630,000,000 yen, redemption date is September 1, 2026.
Read more -
Notice on Monthly Exercise Status (46th Stock Acquisition Rights with Exercise Price Adjustment Clauses)
Disclosure of the monthly exercise status for August 2026 of the 46th stock acquisition rights with exercise price adjustment clauses. For the target month, 0 shares were issued, 0 exercised rights, and unexercised rights remained 837,171; issued shares total 386,077,550...
Read more -
Notice of Payment Completion for Stock Acquisition Rights and Warrantied Bonds Issued via Third-Party Allotment
We disclosed the payment completion for the 47th series of stock acquisition rights (with exercise price adjustment provision) and the 48th series of stock acquisition rights issued via third-party allotment. Details such as total numbers, issue price, potential shares, and...
Read more -
(Correction) Notice regarding partial revisions to the following: 46th Stock Acquisition Rights (exercise price adjustment provisions), termination of the unsecured corporate bond facility (revolving type) overall underwriting, redemption of the 2nd unsecured corporate bond (private placement), 47th Stock Acquisition Right (with exercise price adjustment provisions) through third-party allocation, issuance of 48th Stock Acquisition Right and 2nd unsecured convertible bond-type stock acquisition rights, and the signing of a business alliance agreement with Growth Partners Co., Ltd., and related matters
This correction is a partial amendment to the 14 August 2026 disclosure titled “Notice regarding the 46th stock acquisition rights etc.” The corrections pertain to II. termination of the unsecured bond facility and redemption of the 2nd unsecured bond, III.概要...
Read more
Latest News (5 items)
Company Information
About
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.
